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eft Main Drug-Eluting Stents
atural Progression
r a Bridge Too Far?*
regg W. Stone, MD, FACC,
effrey W. Moses, MD, FACC,
artin B. Leon, MD, FACC
ew York, New York
he left main coronary artery (LMCA) is arguably the most
mportant inch-long structure in the human body, typically
roviding the blood supply for 75% or more of the myocar-
ium. Occurring in approximately 9% of patients undergo-
ng coronary angiography (1,2), symptomatic atherosclerotic
isease of the LMCA managed conservatively (without
evascularization) portends a dire prognosis, with up to a
0% 1-year and 50% 7- to 10-year mortality (3–7). Numer-
us registries and 2 randomized trials have demonstrated a
arked survival advantage of coronary artery bypass graft
CABG) surgery over medical therapy in most subsets of
atients with LMCA disease (5–7). Although performed
ecades ago, these studies continue to define the accepted
tandard of care for patients with obstructive LMCA
isease. Nonetheless, the significant morbidity and mortal-
ty of CABG, as well as the high rate of saphenous vein
raft attrition (which are still used in the majority of CABG
rocedures), has prompted the exploration of lesser invasive
herapies.
See page 491
On first impression, the LMCA might be considered an
ttractive target for percutaneous coronary intervention
PCI); lesions in the LMCA are short, proximally located,
nd readily crossed with a guidewire and balloon. Indeed,
CI of the LMCA was first proposed by no one less than
ndreas Grüentzig (8), who performed balloon dilatation of
n unprotected LMCA as 1 of his first 5 angioplasty
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cientific, Cordis, and Medtronic.rocedures. While many early practitioners cautiously ex-
erimented with LMCA intervention, Geoffrey Hartzler
nd colleagues (9) at St. Luke’s Hospital in Kansas City
xposed the limits of 1980s technology, documenting a high
ate of procedural death (9.4%) and mortality at 3 years
64%) after LMCA balloon angioplasty, with restenosis
ften manifesting as sudden cardiac death. After this report,
he enthusiasm for angioplasty as treatment modality for the
iseased LMCA rapidly waned.
With the introduction of the bare-metal stent (BMS),
MCA intervention was resurrected. By preventing acute
nd chronic recoil and sealing dissection planes, coronary
tents allowed more favorable PCI results to be obtained.
teve Ellis coordinated the ULTIMA (Unprotected Left
ain Trunk Intervention Multicenter Assessment) registry
10), examining the outcomes of 279 patients undergoing
CI of unprotected LMCA lesions (those without the
protection” of a patent bypass graft conduit to either the
eft anterior descending or left circumflex artery) between
993 and 1998 at 25 hospitals (69% with stents). Procedural
ortality still occurred in 13.7% of patients, increasing to
4.2% at 1 year. However, 46% of patients in this series
ere deemed inoperable. Among 89 low-risk patients (age
65 years, left ventricular ejection fraction [LVEF] 30%,
nd no shock), there were no periprocedural deaths, and
urvival at 1 year was 96.6% (10). Other centers subse-
uently demonstrated favorable results in stable patients
ith preserved left ventricular function (11–13). Nonethe-
ess, restenosis rates remained high, especially with involve-
ent of the distal bifurcation, and direct comparisons with
ABG were avoided.
By reducing neointimal proliferation after medial injury,
rug-eluting stents (DES) markedly reduce restenosis and
mprove long-term event-free survival compared with BMS
n noncomplex lesions in patients with stable coronary artery
isease (14,15). Although LMCA lesions were excluded
rom the pivotal randomized trials leading to the U.S.
pproval of sirolimus-eluting and paclitaxel-eluting stents
14,15), their use in this setting has subsequently been
autiously explored (16–21). The results of these registry
nvestigations have varied greatly (reflecting differences in
atient selection, coronary anatomy, and technique), with
eported restenosis rates ranging from 7% to 44%, and
ortality at 6 to 12 months occurring in 0% to 11% of
atients (16–21). While the reintervention rates after DES
or LMCA angioplasty in these series are reduced compared
ith what the same investigators previously achieved with
MS, the use of historical control groups makes definitive
onclusions problematic.
This issue of the Journal contains what will be memori-
lized as an important piece of left main history, the first
andomized trial comparing DES and BMS for LMCA
ntervention (22). Erglis et al. (22) prospectively random-
zed 103 patients at a single center with significant stenosis
f the LMCA to BMS or paclitaxel-eluting stent implan-
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August 7, 2007:498–500 Editorial Commentation, utilizing cutting balloon predilation (to improve
esion compliance) and intravascular ultrasound guidance to
ptimize procedural results. Of note, 77 patients (75%) had
nvolvement of the distal bifurcation, but only 2 patients
eceived multiple stents. Strikingly, no in-hospital deaths
ccurred, and there were only 2 deaths (1.9%, 1 in each
roup) at 6 months, with no episodes of stent thrombosis.
epeat revascularization procedures for recurrent angina or
schemia were required at 6 months in 8 BMS patients
ompared with 1 DES patient (16.0% vs. 1.9%, p  0.01),
benefit attributable to a marked reduction in angiographic
estenosis with the paclitaxel-eluting stent (22.0% vs. 5.7%,
 0.02).
Do these results justify considering DES as a valid
lternative to CABG for the majority of patients with
MCA disease? Numerous unanswered questions must be
ddressed before that bridge can be crossed. Can the
avorable DES results of Erglis et al. (22) be replicated in a
arger, multicenter experience? Are cutting balloon predila-
ion and intravascular ultrasound guidance necessary? What
s the best technique to manage complex disease at the distal
eft main bifurcation (1 vs. 2 stents, and if 2, T-stenting vs.
-stenting vs. crush stenting vs. culotte)? Is there a prefer-
nce between the currently available DES for LMCA
esions, or will outcomes be optimized by emerging specialty
tents designed for the distal bifurcation? Should routine
urveillance angiography be performed to detect asymptom-
tic restenosis? What is the late safety profile of DES in the
MCA, and what is the optimal chronic antiplatelet regi-
en (i.e., for how long is clopidogrel required)? How are
he results impacted by concomitant multivessel disease, left
entricular dysfunction, diabetes, and/or renal insufficiency?
ost importantly, how do the results compare with
ABG?
One small (105 patient) unpublished randomized trial of
tenting (DES or BMS) versus CABG in patients with
nprotected LMCA has, in fact, been completed. In the LE
ANS trial (23), the investigators hypothesized that avoid-
ng cardiopulmonary bypass for the preferential perfor-
ance of PCI would result in improved convalescent left
entricular function, and, indeed, in this study, the resting
VEF rose from similar baseline values to a higher level in
he PCI group at 12 months (60.3  12.6% vs. 54.0 
.1%, p  0.037). With follow-up completed at a mean
uration of 40 months, the survival and angina status were
imilar in both groups, with no occurrences of stent throm-
osis reported.
While these results are intriguing, a large, multicenter
andomized trial of PCI versus CABG is required before
erious consideration can be given to angioplasty supplant-
ng surgery for LMCA disease. Such a study, the SYNTAX
SYNergy between percutaneous coronary intervention with
AXus DES and cardiac surgery) trial, is nearing comple-
ion. In the SYNTAX trial, 1,800 patients with LMCA
nd/or 3-vessel disease (with a minimum of 710 patients
ith significant left main lesions) are being randomized toABG versus PCI with paclitaxel-eluting stents (24). The
rimary end point is the 12-month composite occurrence of
eath, stroke, myocardial infarction, or repeat revasculariza-
ion. The principal results of the SYNTAX trial are antic-
pated in the fall of 2008, and although concerns will be
oiced regarding the limited duration of follow-up and con-
tant evolution of drugs, devices, and techniques, it is likely that
his study will establish the standard to guide revascularization
ecisions for patients with extensive coronary artery disease for
he foreseeable future. Thus, despite the fact that LMCA
tenting with DES is currently a viable treatment alternative in
urope (25), pending SYNTAX, the principles of evidence-
ased medicine would dictate that CABG remain the gold
tandard for most patients with unprotected LMCA disease
ho are good surgical candidates.
eprint requests and correspondence: Dr. Gregg W. Stone,
olumbia University Medical Center, The Cardiovascular Re-
earch Foundation, 111 East 59th Street, 11th Floor, New York,
ew York 10022. E-mail: gs2184@columbia.edu.
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